Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Sponsor: Syndax Pharmaceuticals
Summary
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
468
Start Date
2025-11-25
Completion Date
2031-01
Last Updated
2026-06-24
Healthy Volunteers
No
Conditions
Interventions
Revumenib
Participants will receive revumenib orally.
Placebo
Participants will receive placebo (non-active agent) orally.
Intensive Chemotherapy Regimen
Participants will receive an intensive chemotherapy regimen of cytarabine and daunorubicin by intravenous (IV) infusion.
Locations (52)
Clinical Trial Site
Melbourne, Victoria, Australia
Clinical Trial Site
Gosford, Australia
Clinical Trial Site
Wollongong, Australia
Clinical Trial Site
Linz, Austria
Clinical Trial Site
Ghent, Belgium
Clinical Trial Site
Jaú, Brazil
Clinical Trial Site
Porto Alegre, Brazil
Clinical Trial Site
Montreal, Canada
Clinical Trial Site
Toronto, Canada
Clinical Trial Site
Bayonne, France
Clinical Trial Site
Bordeaux, France
Clinical Trial Site
Batumi, Adjara, Georgia
Clinical Trial Site
Tbilisi, Georgia
Clinical Trial Site 1
Tbilisi, Georgia
Clinical Trial Site 2
Tbilisi, Georgia
Clinical Trial Site
Tbilisi, Georgia
Clinical Trial Site
Düsseldorf, North Rhine-Westphalia, Germany
Clinical Trial Site
Herne, North Rhine-Westphalia, Germany
Clinical Trial Site
Jena, Thuringia, Germany
Clinical Trial Site
Hamburg, Germany
Clinical Trial Site
Jerusalem, Israel
Clinical Trial Site
Jerusalem, Israel
Clinical Trial Site
Bergamo, Italy
Clinical Trial Site
Candiolo, Italy
Clinical Trial Site
Florence, Italy
Clinical Trial Site
Meldola, Italy
Clinical Trial Site
Milan, Italy
Clinical Trial Site
Milan, Italy
Clinical Trial Site
Palermo, Italy
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Rimini, Italy
Clinical Trial Site
Udine, Italy
Clinical Trial Site
Petaling Jaya, Malaysia
Clinical Trial Site
Subang Jaya, Malaysia
Clinical Trial Site
Bucharest, Romania
Clinical Trial Site
Cluj-Napoca, Romania
Clinical Trial Site
Busan, South Korea
Clinical Trial Site
Goyang-si, South Korea
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Badalona, Spain
Clinical Trial Site
Cáceres, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Palma, Spain
Clinical Trial Site
Pamplona, Spain
Clinical Trial Site
Seville, Spain
Clinical Trial Site
Valencia, Spain
Clinical Trial Site
Aberdeen, United Kingdom
Clinical Trial Site
Lincoln, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
Sutton, United Kingdom